請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63299
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃耀輝 | |
dc.contributor.author | De-Lin Wang | en |
dc.contributor.author | 王德麟 | zh_TW |
dc.date.accessioned | 2021-06-16T16:33:32Z | - |
dc.date.available | 2013-05-24 | |
dc.date.copyright | 2013-03-04 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-11-28 | |
dc.identifier.citation | 1. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008;179:1704-8.
2. Li WM, Wu WJ, Li CC, Ke HL, Wei YC, Yeh HC, Chou YH, Huang CH, Huang CN. The effect of tumor location on prognosis in patients with primary ureteral urothelial carcinoma. Urologic Oncology 2012. [Epub ahead of print] 3. Chiang HS, Guo HR, Hong CL, Lin SM, Lee EF. The incidence of bladder cancer in the black foot disease endemic area in Taiwan. British Journal of Urology 1993;71:274-8. 4. Chow WH, Devesa SS, Warren JL, Fraumeni JF. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31. 5. Chiang PH, Huang MS, Tsai CJ, Tsai EM, Huang CH, Chiang CP. Transitional cell carcinoma of the renal pelvis and ureter in Taiwan. DNA analysis by flow cytometry. Cancer 1993;71:3988-92. 6. Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI, Wei ML, Chen HC, Yang HT, Leu LC, Chu TH, Chen Wu C, Yang MH, Chen CJ. Arsenic methylation capacity, body retention, and null genotypes of glutathione s-transferase m1 and t1 among current arsenic-exposed residents in Taiwan. Mutation Research/Reviews in Mutation Research 1997;386:197-207. 7. Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, Hsueh YM. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicology and Applied Pharmacology 2005;206:299-308. 8. Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Chao SC, Lee JY, Christiani DC. Arsenic methylation and skin cancer risk in southwestern Taiwan. Journal of Occupational and Environmental Medicine 2003; 45:241-8. 9. Chen YC, Su HJJ, Guo YLL, Hsueh YM. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes and Control 2003;14:303-10. 10. Wedeen RR, Qiant L. Chromium-induced kidney disease. Environ Health Perspect 1991;92:71-4. 11. Yiin SJ, Chern CL, Sheu JY, Tseng WC, Lin TH. Cadmium induced renal lipid peroxidation in rats and protection by selenium. Journal of Toxicology and Environmental Health 1999;57:403-13. 12. Girelli D, Olivieri O, Stanzial AM, Azzini M, Lupo A, Bernich P, Menini C, Gammaro L, Corrocher R. Low platelet glutathione peroxidase activity and serum selenium concentration in patients with chronic renal failure: relations to dialysis treatments, diet and cardiovascular complications. Clin Sci 1993;84:611-7. 13. Sarto C, Frutiger S, Cappellano F, Sanchez JC, Doro G, Catanzaro F, Hughes GJ, Hochstrasser DF, Mocarelli P. Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma. Electrophoresis 1999;20:3458-66. 14. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001;12:2683-90. 15. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube´ syndrome. Cancer Cell 2002 Aug;2(2):157-64. 16. Il'yasova D, Schwartz GG. Cadmium and renal cancer. Toxicology and Applied Pharmacology 2005;207:179-86. 17. NIOSH. Lead smelters. Available at: http://www.cdc.gov/niosh/topics/lead/WorkerInfo.html. Accessed on July 7,2012. 18. NIOSH. Cadmium recovery workers (cadmium). Available at: http://www.cdc.gov/niosh/pgms/worknotify/cadmium.html. Accessed on June 28,2012. 19. Lesley AS, Josef C, Tom G, Andrew SL. Assessing kidney function — measured and estimated glomerular filtration rate. New England Journal of Medicine 2006;354:2473-83. 20. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85. 21. 衛生署,2009。98年國人主要死因統計(以ICD-10編碼). Accessed on May, 2012 at http://www.doh.gov.tw/CHT2006/DM/DM2_p01.aspx?class_no=25&level_no=1&doc_no=76013。 22. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases 2003;41:1-12. 23. Tsai HL, Chin TW, Chang JW, Liu CS, Wei CF. Renal cell carcinoma in children and young adults. Journal of the Chinese Medical Association 2006;69:240-4. 24. Frank I, Blute M, Cheville J, Lohse C, Weaver A, Zincke H. Solid renal tumors: An analysis of pathological features related to tumor size. The Journal of Urology 2003;170:2217-20. 25. Fujii Y, Komai Y, Saito K, Iimura Y, Yonese J, Kawakami S, Ishikawa Y, Kumagai J, Kihara K, Fukui I. Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients. Urology 2008 Sep;72(3):598-602. 26. Boffetta P, Fontana L, Stewart P, Zaridze D, Szeszenia Dabrowska N, Janout V, Bencko V, Foretova L, Jinga V, Matveev V, Kollarova H, Ferro G, Chow WH, Rothman N, van Bemmel D, Karami S, Brennan P, Moore LE. Occupational exposure to arsenic, cadmium, chromium, lead and nickel, and renal cell carcinoma: a case-control study from Central and Eastern Europe. Occup Environ Med 2011 Oct;68(10):723-8. 27. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England Journal of Medicine 2007 May 31;356(22):2271-81. 28. Lipworth L, Tarone RE, McLaughlin JK. Renal cell cancer among African Americans: an epidemiologic review. BMC Cancer 2011 Apr 12;11:133. 29. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998 Jul;22(3):200-9. 30. Bellocco R, Pasquali E, Rota M, Bagnardi V, Tramacere I, Scotti L, Pelucchi C, Boffetta P, Corrao G, La Vecchia C. Alcohol drinking and risk of renal cell carcinoma: results of a meta-analysis. Ann Oncol 2012 Sep;23(9):2235-44. 31. Seitz C, Gupta A, Shariat SF, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Otto W, Tritschler S, Bastian PJ, Carballido J, Ficarra V, Karakiewicz PI, Artibani W, Mazzoleni G, Novara G. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: An international validation study. The Journal of Urology 2010;184:1895-900. 32. Rabbani F, Perrotti M, Russo P, Herr HW. Upper tract tumors after an initial diagnosis of bladder cancer: Argument for long term surveillance. J Clin Oncol 2001 Jan 1;19(1):94-100. 33. Kao YL, Ou YC, Yang CR, Chung HH, Su CK, Shu KH. Transitional cell carcinoma in renal transplant recipients. World Journal of Surgery 2003;27:912-6. 34. Liem V, Thon W, Krautzig S, Kolditz M, Behrend M, Pichlmayr R, Koch KM, Frei U, Brunkhorst R. High mortality from urothelial carcinoma despite regular tumor screening in patients with analgesic nephropathy after renal transplantation. Transplant International 1996;9:231-5. 35. Gonwa TA, Corbett WT, Schey HM, Buckalew VM. Analgesic associated nephropathy and transitional cell carcinoma of the urinary tract. Annals of Internal Medicine 1980;93:249-52. 36. Rink M, Adam M, Hansen J, Chun FK, Ahyai SA, Remzi M, Schlomm T, Engel O, Heuer R, Eichelberg C, Fisch M, Dahlem R, Shariat SF. Upper tract urothelial carcinoma : An update on clinical and pathological prognostic factors. Urologe 2012 Sep;51(9):1228-39. 37. Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C. Chinese herbs nephropathy: A clue to Balkan endemic nephropathy? Kidney Int 1994;45:1680-8. 38. Morais S, Costa FG, Pereira ML. Heavy metals and human health. Environmental Health 2006;10:227-46. 39. Vieira C, Morais S, Ramos S, Delerue Matos C, Oliveira MB. Mercury, cadmium, lead and arsenic levels in three pelagic fish species from the Atlantic Ocean: intra- and inter-specific variability and human health risks for consumption. Food Chem Toxicol 2011;49:923-32. 40. Desoize B. Metals and metal compounds in cancer treatment. Anticancer Res 2004;24:1529-44. 41. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY. Use of arsenic trioxide (As2O3 ) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997 May 1;89(9):3354-60. 42. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999;131:88-95. 43. Kondo Y, Satoh M, Imura N, Akimoto M. Tissue-specific induction of metallothionein by bismuth as a promising protocol for chemotherapy with repeated administration of cis-diamminedichloroplatinum (II) against bladder tumor. Anticancer Res 1992 Nov-Dec;12(6B):2303-7. 44. James FF, Daniel B, Patricia S. Cancer in rheumatoid arthritis: a prospective long-term study of mortality. Am J Med 1985;78(1):56–59. 45. Edward RT. Gold derivatives for the treatment of cancer. Rev Oncol Hematol 2002; 42(3):225–248. 46. English LH, Macara IG, Cantley LC. Vanadium stimulates the (Na+,K+) pump in friend erythroleukemia cells and blocks erythropoiesis. J Cell Biol 1983 Oct;97(4):1299-302. 47. Thompson HJ, Chasteen ND, Meeker LD. Dietary vanadyl(IV) sulfate inhibits chemically-induced mammary carcinogenesis. Carcinogenesis 1984 Jun;5(6):849-51. 48. Hanauske U, Hanauske AR, Marshall MH, Muggia VA, Von Hoff DD. Biphasic effect of vanadium salts on in vitro tumor colony growth. Int J Cell Cloning 1987 Mar;5(2):170-8. 49. Wang F, Elliott RL, Head JF. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res 1999 Jan-Feb;19(1A):445-50. 50. Kemp JD, Cardillo T, Stewart BC, Kehrberg E, Weiner G, Hedlund B, Naumann PW. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res 1995 Sep 1;55(17):3817-24. 51. Burger RM, Adler AD, Horwitz SB, Mims WB, Peisach J. Demonstration of nitrogen coordination in metal bleomycin complexes by electron spin echo envelope spectroscopy. Biochemistry 1981 Mar 17;20(6):1701-4. 52. Meng X, Korfiatis GP, Christodoulatos C, Bang S. Treatment of arsenic in Bangladesh well water using a household co-precipitation and filtration system. Water Research 2001;35:2805-10. 53. Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989;130:1123-32. 54. Lamm SH, Byrd DM, Kruse MB, Feinleib M, Lai SH. Bladder cancer and arsenic exposure: differences in the two populations enrolled in a study in southwest Taiwan. Biomed Environ Sci 2003;16:355-68. 55. Chen CJ, Hsu LI, Tseng CH, Hsueh YM, Chiou HY. Emerging epidemics of arseniasis in Asia. Elsevier Science B 1999;113-21. 56. Rich CH, Biggs ML, Smith AH. Lung and kidney cancer mortality associated with arsenic in drinking water in Córdoba, Argentina. International Journal of Epidemiology 1997;27(4) 561-69. 57. Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, Chen CJ. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001;153:411-8. 58. Guo HR. Cancer risks associated with arsenic in drinking water. Environ Health Perspect 2007 July; 115(7): A339–A340. 59. Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, Goyer R, Menzer R, Rossman T, Thompson C, Waalkes M. Arsenic: health effects, mechanisms of actions, and research issues. Environmental Health Perspectives 1999;53:85-93. 60. Tapio S, Grosche B. Arsenic in the aetiology of cancer. Mutation Research/Reviews in Mutation Research 2006;612:215-46. 61. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2002;181–182:211-7. 62. Thomas DJ, Waters SB, Styblo M. Elucidating the pathway for arsenic methylation. Toxicology and Applied Pharmacology 2004;198:319-26. 63. Vasken AH, Zakharyan RA, Avram MD, Sampayo RA, Wollenberg ML. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicology and Applied Pharmacology 2004;198:327-35. 64. Hirano S, Kobayashia Y, Cuia X, Kannoa S, Hayakawaa T, Shraimb A. The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicology and Applied Pharmacology 2004;198:458-67. 65. Chen CJ, Chiou HY. Chen and Chiou respond to “arsenic and cancer of the urinary tract”. Am J Epidemiol 2001;153(5): 422-423. 66. Cantor KP. Invited commentary: arsenic and cancer of the urinary tract. Am J Epidemiol 2001 Mar 1;153(5):422-3. 67. Selevan SG, Landrigan PJ, Stern FB, Jones JH. Mortality of lead smelter workers. Am J Epidemiol 1985;122(4): 673-83. 68. Steenland K, Selevan S, Landrigan P. The mortality of lead smelter workers: an update. Am J Public Health 1992 Dec;82(12):1641-4. 69. Cocco P, Hua F, Boffetta P, Carta P, Flore C, Flore V, Onnis A, Picchiri GF, Colin D. Mortality of Italian lead smelter workers. Scand J Work Environ Health 1997 Feb;23(1):15-23. 70. Jarup L, Berglund M, Elinder CG, Nordberg G, Vahter M. Health effects of cadmium exposure: a review of the literature and a risk estimate. Scand J Work Environ Health 1998;24 Suppl 1:1-51. 71. Kolonel LN. Association of cadmium with renal cancer. Cancer 1976;37:1782-7. 72. Schottenfeld D. Cancer epidemiology and prevention. Oxford University Press 1996. 73. Kolonel LN. Association of cadmium with renal cancer. Cancer 1976;37(4):1782-87 74. Nordberga GF, Jina T, Hongc F, Zhangc A, Buchetd JP, Bernardd A. Biomarkers of cadmium and arsenic interactions. Toxicol Appl Pharmacol 2005;206(2):191-7 75. Hong F, Jin T, Zhang A. Risk assessment on renal dysfunction caused by co-exposure to arsenic and cadmium using benchmark dose calculation in a Chinese population. Biometals 2004 Oct;17(5):573-80. 76. de Burbure C, Buchet JP, Leroyer A, Nisse C, Haguenoer JM, Mutti A, Smerhovsky Z, Cikrt M, Trzcinka-Ochocka M, Razniewska G, Jakubowski M, Bernard A. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect 2006;114:584-90. 77. Calvo FB, Santos Junior D, Rodrigues CJ, Krug FJ, Marumo JT, Schor N, Bellini MH. Variation in the distribution of trace elements in renal cell carcinoma. Biol Trace Elem Res 2009 Aug;130(2):107-13. 78. Dobrowolski Z, Drewniak T, Kwiatek W, Jakubik P. Trace elements distribution in renal cell carcinoma depending on stage of disease. European Urology 2002;42:475-80. 79. Marchiset-Ferlay N, Savanovitch C, Sauvant-Rochat MP. What is the best biomarker to assess arsenic exposure via drinking water? Environment International 2012;39:150-71. 80. Nordberg G, Jin T, Wu X, Lu J, Chen L, Liang Y, Lei L, Hong F, Bergdahl IA, Nordberg M. Kidney dysfunction and cadmium exposure factors influencing dose–response relationships. Journal of Trace Elements in Medicine and Biology 2012;26:197-200. 81. Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 2010 Jun 15;116(12):2967-73. 82. Chang CH, Yang CM, Yang AH. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 2007;109(8):1487–92. 83. Feldmann J, Lai VWM, Cullen WR, Ma M, Lu X, Le XC. Sample preparation and storage can change arsenic speciation in human urine. Clin Chem 1999 Nov;45(11):1988-97. 84. 衛生署,2011。2010 - 2011台灣國民營養健康狀況變遷調查結果. Accessed on May, 2012 at http://consumer.fda.gov.tw/Pages/List.aspx?nodeID=507. 85. Cullen WR, McBride BC, Manji H, Pickettj AW, Regtinski J. The metabolism of methylarsine oxide and sulfide. Applied Organometallic Chemistry 1989;3(1):71-78. 86. Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002;17:265-77. 87. Wang JD. Urinary tract cancer associated with chinese herbal products containing aristolochic acid. Available at: http://jnci.oxfordjournals.org/content/early/2009/12/23/jnci.djp522.full. Accessed on June 21, 2012. 88. Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. American Journal of Kidney Diseases 2000;35:313-8. 89. Imai E, Matsuo S. Chronic kidney disease in Asia. The Lancet 2008; 371: 2147–8. 90. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu CC, Sung PK, Hsu YH, Wen SF. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462293 adults in Taiwan. Lancet 2008 Jun 28;371(9631):2173-82. 91. Hsieh CF, Huang SL, Chen CL, Chen WT, Chang HC, Wu ML, Yang CC. Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan. Preventive Medicine 2012;55:155-9. 92. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP. Aristolochic acid-associated urothelial cancer in Taiwan. Proceedings of the National Academy of Sciences 2012;109:8241-6. 93. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996 May 1;56(9):2025-8. 94. IARC. Arsenic and arsenic compounds. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. World Health Organization, International Agency for Research on Cancer, Switzerland, 1987. 95. Gibb H, Chen CW. Is inhaled arsenic carcinogenic for sites other than the lung. Springer Verlag: Berlin 1989. 96. Bongiovanni G, Soria EA, Eynard AR. Effects of the plant flavonoids silymarin and quercetin on arsenite induced oxidative stress in CHO K1 cells. Food Chem Toxicol 2007 Jun;45(6):971-6. 97. Jaymie M, Robert W, Lorraine C, Jerome N. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health 2007 Feb 2;6:4. 98. Soria E, Goleniowski M, Cantero J, Bongiovanni G. Antioxidant activity of different extracts of Argentinean medicinal plants against arsenic- induced toxicity in renal cells. Hum Exp Toxicol 2008;27:341-6 99. Hu J, Mao Y, White K. Renal cell carcinoma and occupational exposure to chemicals in Canada. Occup Med 2002 May;52(3):157-64. 100. Hsueh YM, Ko YF, Huang YK, Chen HW, Chiou HY, Huang YL, Yang MH, Chen CJ. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol Lett 2003 Jan 31;137(1-2):49-63. 101. Chen CJ, Chuang YC, Lin lM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 1985 Nov;45(2):5895-9. 102. Blackwell RQ, Kao TC, Tseng WP. Preliminary report on arsenic hair and urine excretion of subjects from the endemic blackfoot area. J Fermosan Med Assoc 1960;60:1351-52. 103. Valentine JL, Kang HK, Spivey G. Arsenic levels in human blood, urine, and hair in response to exposure via drinking water. Environmental Research 1979;20:24-32. 104. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, Lue LC, Chen GS, Chen CJ. Serum beta carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol 1997;6:589-96. 105. Hsueh YM, Ko YF, Huang YK, Chen HW, Chiou HY, Huang YL, Yang MH, Chen CJ. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol Lett 2003 Jan 31;137(1-2):49-63. 106. Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, Chiu AW, Yang MH, Chen CJ, Hsueh YM. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicology and Applied Pharmacology 2007;218:99-106. 107. Francesconi KA, Tanggaar R, McKenzie CJ, Goessler W. Arsenic metabolites in human urine after ingestion of an arsenosugar. Clin Chem 2002 Jan;48(1):92-101. 108. Sakurai T. Review: Biological effects of organic arsenic compounds in seafood. Applied Organometallic Chemistry 2002;16:401-5. 109. ATSDR. Public health statement for chromium. Available at: http://www.atsdr.cdc.gov/phs/phs.asp?id=60&tid=17. Accessed on May 7,2012. 110. Vincent AO, Steven OA, Felix E, Ize Iyamu OK, Veronica AA, Jato OE, Benedict OE, Patrick O, Kehinde AJ, Mathew O, Medjor WO. A comparative evaluation and toxicity assessment of heavy metals in commonly smoked cigarette brands and local tobacco snuff purchased and consumed in Nigeria. Research Journal of Environmental Toxicology 2011;5(6): 359-68 111. Minoia C, Apostoli P, Maranelli G, Baldi C, Pozzoli L, Capodaglio E. Urinary chromium levels in subjects living in two north Italy regions. Science of The Total Environment 1988;71:527-31. 112. Nordenson I, Beckman L. Is the genotoxic effect of arsenic mediated by oxygen free radicals? Hum Hered 1991;41:71-3. 113. Anand SS. Protective effect of vitamin B6 in chromium-induced oxidative stress in liver. Journal of Applied Toxicology 2005;25:440-3. 114. Tainer J, Getzoff E, Richardson J, Richardson D. Structure and mechanism of copper, zinc superoxide dismutase. Nature 1983;306:284-7. 115. Bettger WJ, Fish TJ, O'Dell BL. Effects of copper and zinc status of rats on erythrocyte stability and superoxide dismutase activity. Proc Soc Exp Biol Med 1978;158:279-82. 116. Moulis JM. Cellular mechanisms of cadmium toxicity related to the homeostasis of essential metals. BioMetals 2010;23:877-96. 117. Ciccarelli RB, Hampton TH, Jennette KW. Nickel carbonate induces DNA-protein crosslinks and DNA strand breaks in rat kidney. Cancer Letters 1981;12:349-54. 118. Barceloux DG. Selenium. J Toxicol Clin Toxicol 1999;37(2):145-72. 119. Bobcek B. Effects of dietary organic selenium supplementation on selenium content, antioxidative status of muscles and meat quality of pigs. Czech J Anim Sci 2004;49:411-7. 120. Sugiyama S, Hayakawa M, Kato T, Hanaki Y, Shimizu K, Ozawa T. Adverse effects of anti-tumor drug, cisplatin, on rat kidney mitochondria: Disturbances in glutathione peroxidase activity. Biochemical and Biophysical Research Communications 1989;159:1121-7. 121. Misra M, Rodriguez RE, Kasprzak KS. Nickel induced lipid peroxidation in the rat: correlation with nickel effect on antioxidant defense systems. Toxicology 1990;64:1-17. 122. Ko YF. The relationship between urine selenium levels and inorganic arsenic methylation capability among residents of lanyang basin in taiwan: Taipei Medical University, Taipei, 2000. 123. Levine T. Special report on ingested inorganic arsenic : skin cancer, nutritional essentiality. Risk Assessment Forum, U.S. Environmental Protection Agency, Taipei, 1988. 124. Vahter M. Species differences in the metabolism of arsenic compounds. Applied Organometallic Chemistry 1994;8:175-82. 125. Yoshinaga J, Chatterjee A, Shibata Y, Morita M, Edmonds JS. Human urine certified reference material for arsenic speciation. Clinical Chemistry 2000;46:1781-6. 126. Feldmann J, Lai VW, Cullen WR, Ma M, Lu X, Le XC. Sample preparation and storage can change arsenic speciation in human urine. Clinical Chemistry 1999;45:1988-97. 127. Von CD, Denkhaus E, Lemke K. Determination of trace element distribution in cancerous and normal human tissues by total X-ray fluorescence analysis. Spectrochim Acta 1997;52:1047-1052 128. Bhuloka RS, Charlesa JM, Rajua GN, Vijayanb V, Reddya BS, Kumara MR, Sundareswarc B. Trace elemental analysis of carcinoma kidney and stomach by PIXE method. Nucl Instr Meth Phys Res 2003;207:345-355. 129. Yaman M, Kaya G, Yekeler H. Distribution of trace metal concentrations in paired cancerous and non-cancerous human stomach tissues. World J Gastroenterol 2007;13(4):612-618. 130. Farah IO, Trimble Q, Ndebele K, Mawson A. Significance of differential metal loads in normal versus cancerous cadaver tissues. Biomed Sci Instrum 2010;46:404-9. 131. Siddiqui MK, Jyoti, Singh S, Mehrotra PK, Singh K, Sarangi R. Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: An Indian study. Environment International 2006;32:630-7. 132. Epstein L, Bassein S. Pesticide applications of copper on perennial crops in California, 1993 to 1998. J Environ Qual 2001;30:1844-7. 133. Wanigasuriya KP, Peiris-John RJ, Wickremasinghe R, Hittarage A. Chronic renal failure in north central province of Sri Lanka: an environmentally induced disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007;101:1013-7. 134. Mielke HW, Powell ET, Shah A, Gonzales CR, Mielke PW. Multiple metal contamination from house paints: consequences of power sanding and paint scraping in New Orleans. Environ Health Perspect 2001 Sep;109(9):973-8. 135. Singh N, Turner A. Trace metals in antifouling paint particles and their heterogeneous contamination of coastal sediments. Marine Pollution Bulletin 2009;58:559-64. 136. Orisakwe OE, Nwachukwu E, Osadolor HB, Afonne OJ, Okocha CE. Liver and kidney function tests amongst paint factory workers in Nkpor, Nigeria. Toxicology and Industrial Health 2007;23:161-5. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63299 | - |
dc.description.abstract | 背景:泌尿上皮移形細胞癌在台灣的發生率較西方國家高,佔台灣地區的腎臟癌發生率一半以上。先前研究顯示,鉻、錳、銅、砷、鎘、鉛及鎳金屬對腎臟及泌尿道系統會產生不良健康效應,有高砷暴露且砷代謝功能較差的人,其發展為周邊血管系統疾病的危險性較高。本研究目的在探討腎臟癌發生是否與腎臟各部位組織內之砷濃度或是其他金屬濃度有關。此外,也比較砷代謝功能的差異是否與腎臟癌發病有關。
方法:本研究收集102名進行腎臟器官摘除手術的個案,包括腎細胞癌個案、泌尿上皮移形細胞癌個案及對照個案。收取研究個案尿液樣本,並從摘除的腎臟器官取得腎臟皮質、腎盂、輸尿管等組織樣本,各樣本再以感應耦合電漿質譜儀分析,分析金屬包括鉻、錳、銅、砷、硒、鍶、鎘、鉛、鎳等元素;並利用液相層析儀串聯感應耦合電漿質譜儀分析尿液中之砷物種,包括三價砷、五價砷、單甲基砷酸、雙甲基砷酸等。另以問卷調查方式收集個案的基本資料及影響環境金屬暴露因子資料,以與各種腎臟組織樣本中金屬濃度進行相關性比較。 結果:腎細胞癌個案尿液中鎘平均濃度為6.77 ± 13.3 µg / L,泌尿上皮移形細胞癌個案為2.30 ± 4.60 µg / L,兩組研究個案間具統計上顯著差異。腎細胞癌個案腎臟皮質中的錳與銅的平均濃度分別為3.24 ± 2.05 µg / g、9.51 ± 3.98 µg / g,皆顯著高於泌尿上皮移形細胞癌個案腎臟皮質的錳濃度2.07 ± 1.52 µg / g、銅濃度6.10 ± 4.84 µg / g。另外,腎細胞癌個案組中腎臟皮質腫瘤組織的銅、硒、鎘與鉛濃度皆小於其週邊正常組織中的相對應金屬濃度,其濃度差值平均分別是-6.21 ± 6.46 µg / g (p = 0.01)、-2.65 ± 2.81 µg / g (p = 0.01)、-87.5 ± 73.8 µg / g (p = 0.003)、-1.97 ± 2.69 µg / g (p = 0.04)。此外,各種腎臟組織樣本與尿液中總砷濃度、砷物種比例及PMI、SMI兩項指標等,在三組研究個案間沒有達到統計上的顯著差異。 結論:過往研究指出,暴露到鉻、錳、銅、砷、鎘、鉛及鎳金屬可能與泌尿道系統病變有關,而本研究結果雖有發現尿液中的鎘濃度及腎臟皮質組織中的錳、銅濃度在腎細胞癌與泌尿上皮移行細胞癌二組研究個案間有統計差異,但並未發現尿液中的總砷與砷物種濃度在個案間有顯著差異,因此本研究結果尚不足以說明尿液中總砷與砷物種作為腎臟癌相關風險指標的可行性。另外,銅、硒、鎘、鉛等金屬濃度在腎細胞癌腫瘤組織高於正常組織,這些不同類別金屬濃度在腎臟腫瘤組織與正常組織間分布差異的影響機制值得進一步深入探討。 | zh_TW |
dc.description.abstract | Background:The upper tract urothelial carcinoma accounted for more than half of kidney cancer in Taiwan, and its incidence was higher than those of the western countries. Previous studies indicated that chromium, manganese, copper, arsenic, cadmium, lead and nickel may cause adverse health effects in kidney and urinary tract. People with deficit in arsenic metabolism tended to develop peripheral vascular disease after exposing to high level of arsenic. The goals of this study were set to explore the association between the occurrence of kidney cancers and the concentrations of arsenic or other relevant metals in various kidney tissues, and between the occurrence of kidney cancers and the efficacy of arsenic metabolism in human body.
Methods:One hundred and two patients with excision surgery for kidney cancers, including renal cell carcinoma, upper tract urothelial cancer, and controls were recruited from the National Taiwan University Hospital. Urine samples and renal cortex, pelvis samples and urothelial tract samples from the excised organs were collected from each study subject. Concentrations of chromium, manganese, copper, arsenic, selenium, strontium, cadmium, lead, nickel in the collected tissue and urine samples were analyzed by inductively coupled plasma mass spectrometer while the levels of trivalent arsenic, pentavalent arsenic, monomethylarsonic acid, dimethylarsinic acid in urine samples were analyzed with high performance liquid chromatography along with inductively coupled plasma mass spectrometry. Demographics and environmental metal exposure factors of the study subjects were collected by questionnaire administration in order to compare their effects on the study metal levels in urine and kidney tissue samples. Results: Average cadmium concentration in urine samples of the renal cell carcinoma cases, 6.77 ± 13.3 μg/L, was higher than that of upper tract urothelial cancer cases, 2.30 ± 4.60 μg/L (p <0.05). The average concentrations of manganese and copper in the renal cortex in the cases of renal cell carcinoma were significantly higher than those of the upper tract urothelial cancer cases. Average manganese and copper concentrations in renal cortex samples of the renal cell carcinoma cases were 3.24 ± 2.05 μg/g and 9.51 ± 3.98 μg/g, respectively, both significantly higher than those of the upper tract urothelial cancer cases; 2.07 ± 1.52 μg/g and 6.10 ± 4.84 μg/g, respectively. In addition, concentrations of copper, selenium, cadmium and lead in tumor tissues of the renal cortex samples of the renal cell carcinoma cases were all lower than those in the adjacent normal tissues with differences of 6.21 ± 6.46 µg/g (p=0.01), 2.65±2.81 µg/g (p=0.01), 87.5±73.8 µg/g (p=0.003), 1.97±2.69 µg/g (p=0.04). Furthermore, there was no difference in total arsenic levels in various renal tissue samples, and in proportion of arsenic species, PMI and SMI index for urine samples, among the renal cell carcinoma cases, the upper tract urothelial carcinoma cases, and the controls. Conclusions: Previous studies reported that exposure to chromium, manganese, copper, arsenic, cadmium, lead and nickel might be associated with urinary tract related diseases. However, although this study found there were differences in urinary cadmium concentration and in manganese, copper concentrations in renal cortex samples between renal cell carcinoma cases and upper tract urothelial cancer cases, there was no difference observed for total urinary arsenic levels and urinary arsenic species among the renal cell carcinoma cases, the upper tract urothelial cancer cases and the control cases. Therefore, results of the present study might not be appropriate to support the use of total urinary arsenic level and urinary arsenic species levels as indicators for renal cancer related risk. Besides, the concentrations of copper, selenium, cadmium, lead in tumor tissue of the renal cell carcinoma cases were found higher than those of their adjacent normal tissue. The mechanism leading to such metal concentration gradient between tumor and normal tissues in kidney is deserved of future study for further exploration. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T16:33:32Z (GMT). No. of bitstreams: 1 ntu-101-R99841013-1.pdf: 752219 bytes, checksum: 3874b313b1c6a4539b59bad51ddd5949 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 目 錄
摘要 I ABSTRACT III 第一章 前言 1 1.1研究背景 1 1.2研究目的 3 第二章 文獻探討 4 2.1腎臟作用與金屬 4 2.2腎臟癌簡介 4 2.2.1腎細胞癌(renal cell carcinoma, RCC) 5 2.2.2泌尿上皮移形細胞癌(upper tract urothelial cancer, UTUC) 6 2.3金屬與癌症的關係 7 2.3.1 金屬與泌尿道系統 9 2.4腎臟與生理、生化指標 11 第三章 材料與方法 13 3.1研究對象 13 3.2問卷設計 14 3.3儀器設備 15 3.3.1生物檢體金屬濃度分析 15 3.3.2試藥與試劑 15 3.3.3 ICP-MS介紹 17 3.3.4生物樣本收集及處理 19 3.3.4.1尿液樣本收集 19 3.3.4.2腎臟組織樣本收集 20 3.3.4.3尿液樣本之前處理 20 3.3.4.4組織樣本之前處理 20 3.3.4.5尿液樣本多元素分析檢量線配製 21 3.3.4.6 腎臟組織樣本多元素分析檢量線配製 22 3.3.4.7尿液多元素分析檢量線配製 24 3.4分析方法之品質控制 26 3.4.1儀器調校 26 3.4.2 樣本分析 26 3.4.3 品質控制 26 3.4.4偵測極限 31 3.4.5標準參考樣本分析 31 3.5統計分析 32 第四章 研究結果 34 4.1受試者基本資料 34 4.2尿液與腎臟組織檢體金屬濃度分析情形 39 4.2.1尿液中金屬濃度分布 39 4.2.2尿液中金屬濃度分布與影響因子之關係 40 4.3腎臟組織中金屬濃度分布情形 56 4.3.1腎臟癌個案皮質組織中金屬濃度分布 56 4.3.2腎臟癌個案腫瘤組織與正常組織金屬濃度之差異 58 4.4尿液中砷物種之分布情形 60 4.5尿液中金屬濃度影響因子複迴歸模式分析 64 第五章 討論 66 5. 1 中草藥與腎臟癌 66 5. 2 研究個案尿液中砷物種濃度分布與腎臟癌之關係 66 5. 3 尿液中鉻濃度分布與影響因子 68 5. 4 尿液中硒及其他金屬濃度分布與影響因子 68 5. 5 尿液中砷物種濃度分布與腎臟癌 69 5. 6 腎臟癌腫瘤組織與正常組織之金屬濃度 70 5. 7 農藥及油漆的使用習慣與腎臟癌之相關探討 71 第六章 研究限制 72 6.1本研究之限制 72 第七章 參考文獻 73 第八章 附錄 85 | |
dc.language.iso | zh-TW | |
dc.title | 尿液中無機砷代謝物種及腎臟皮質、腎盂、輸尿管金屬分布與腎臟癌關係之探討 | zh_TW |
dc.title | Study on the Association of Urinary Inorganic Arsenic Metabolites and Metal Concentrations in Renal Cortex, Pelvis, Ureter with Kidney Cancers | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳保中,王碩盟 | |
dc.subject.keyword | 腎細胞癌,泌尿上皮移行細胞癌,腎臟皮質,腎盂,輸尿管,尿液,鉻,錳,銅,鎘,鉛,鎳,砷物種, | zh_TW |
dc.subject.keyword | renal cell carcinoma,upper tract urothehial cancer,renal cortex,pelvis,urinary tract,urine,chromium,manganese,copper,cadmium,lead,nickel,arsenic species, | en |
dc.relation.page | 91 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-11-29 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 職業醫學與工業衛生研究所 | zh_TW |
顯示於系所單位: | 職業醫學與工業衛生研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 734.59 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。